Is this biotech built on lasting therapies?
Biogen is a biotechnology company focused on developing and commercializing therapies for neurological and neurodegenerative diseases. Its business is built around bringing prescription medicines to market and supporting them through ongoing manufacturing and commercial distribution. The company operates at a large-cap scale, with a market value around USD 32 billion. For most investors, the real question is how dependable Biogen’s earnings power is across product cycles.
Are margins and cash flow holding steady?
FundamentalsFor 2025, reported in USD, revenue was about USD 9.9 billion, up 2.2% year over year, alongside net income of roughly USD 1.3 billion. Profitability remained supported by a 75.49% gross margin, with operating margin at 17.47% and net margin at 13.81% over the trailing period.
Cash on hand was about USD 3.0 billion against total debt of roughly USD 0.8 billion. Depreciation and amortization were around USD 780 million, while capital spending was about USD 150 million, keeping reinvestment demands relatively small in dollar terms versus the company’s revenue base.
Is the market underpricing steady profits?
DCF / MultiplesAt USD 216.63, the current price sits below the discounted cash flow range derived from both weaker and stronger scenarios. The market’s headline pricing also frames Biogen at about 23.31x trailing earnings and 15.38x EV/EBITDA, with a trailing price-to-sales ratio of 3.22.
Durability Over Growth
TakeawayThe price looks like it doubts long-lived earning power. The case works if margins and profits stay resilient. Durability matters more here than fast growth. If profits fade, the valuation support weakens quickly.